Silicone Breast Implant Study and Breast Cancer Risk: Questions and Answers
![](https://webarchive.library.unt.edu/eot2008/20080925075441im_/http://www.cancer.gov/images/spacer.gif) |
Key Points
|
![](https://webarchive.library.unt.edu/eot2008/20080925075441im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20080925075441im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20080925075441im_/http://www.cancer.gov/images/spacer.gif) |
-
What is the purpose of the breast implant study? The National Cancer
Institute (NCI) is conducting a study to determine the long-term health effects
associated with silicone breast implants, including any changes in breast
cancer risk. Although implants have been linked to various short-term
complications, less is known about their long-range effects. (Question 1)
-
Why was the study initiated? Breast implants were first marketed in the
early 1960s, before the 1976 Medical Device Amendments to the Food, Drug and
Cosmetic Act required that medical devices be shown to be safe and effective.
Silicone was initially assumed by manufacturers to be biologically inactive
and, therefore, to have no harmful effects. However, cases of connective tissue
disorders and cancers were reported in several short-term studies. (Question 2)
-
Who are the participants in the study? The participants include 13,500
women who had implant surgery for cosmetic reasons in both breasts before 1989.
For comparison, about 4,000 women similar in age who had some other type of
plastic surgery, such as removal of fat from the stomach or wrinkles from the
face or neck, were identified. (Question 3)
![](https://webarchive.library.unt.edu/eot2008/20080925075441im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20080925075441im_/http://www.cancer.gov/images/spacer.gif) |
|
1. What is the purpose of the breast implant study?
The National Cancer Institute (NCI) is conducting a study to determine the
long-term health effects associated with silicone breast implants, including
any changes in breast cancer risk. Although implants have been linked to
various short-term complications, less is known about their long-range effects.
The current study, evaluating breast cancer risk and breast implants, appears
in the November issue of Cancer Causes and Control
.
Future analyses will evaluate the occurrence of other cancers and connective
tissue disorders, as well as the causes of death. The characteristics of the
13,500 participants and 4,000 comparison patients in the study are described in
a paper published in March 2000 (see question 7).
2. Why was the study initiated?
Breast implants were first marketed in the early 1960s, before the 1976 Medical
Device Amendments to the Food, Drug and Cosmetic Act required that medical
devices be shown to be safe and effective. Silicone was initially assumed by
manufacturers to be biologically inactive and, therefore, to have no harmful
effects. However, cases of connective tissue disorders and cancers were
reported in several short-term studies.
Because there were few reports on the long-term safety of implants, in 1992,
the Food and Drug Administration (FDA) restricted the use of silicone gel
breast implants to controlled clinical trials of women seeking breast
reconstruction. To address many of the unanswered questions, Congress directed
the National Institutes of Health in the same year to undertake a large
follow-up study to assess the long-term health effects of exposure to silicone
breast implants.
It is estimated that between 1.5 and two million women in this country have had
breast implants since they first appeared on the market. Before the 1992 FDA
ban, implants were typically made of a silicone shell filled with silicone gel,
with saline-filled implants being less popular. Currently, it is not known how
many women have silicone vs. saline implants, but women with both types of
implants are included in the NCI study.
3. What are the principal findings of the study?
-
The authors found no association between breast implants and the risk of
subsequent breast cancer.
-
There was no association of breast cancer risk with years of follow-up.
-
Breast cancer risk was not associated with any particular type of implant.
-
Breast tumors tended to be detected at a somewhat later stage among breast
implant patients than among the control group, but the difference was not
statistically significant and could be due to chance.
-
There was no significant difference in breast cancer mortality between the
implant and comparison patients.
4. Who are the participants in the study?
The participants include 13,500 women who had implant surgery for cosmetic
reasons in both breasts before 1989. For comparison, about 4,000 women similar
in age who had some other type of plastic surgery, such as removal of fat from
the stomach or wrinkles from the face or neck, were identified. All
participants were from 18 plastic surgery practices in six geographic areas
(Atlanta, Ga.; Birmingham, Ala.; Charlotte, N.C.; Miami and Orlando, Fla.; and
Washington, D.C.). The practices were chosen because the plastic surgeons had
performed large numbers of cosmetic breast implant surgeries prior to 1989 and
were willing to give the investigators access to their records.
5. What is the design of the study?
The medical records from the plastic surgery practices were reviewed to
identify patients who were eligible for the study. For eligible patients,
trained medical records abstractors collected information about the surgical
procedures, the type of implant, anycomplications, and factors which might
affect health status, such as weight or medical history.
Patients were then traced through a variety of sources. Living subjects were
asked to complete a mailed questionnaire to collect information about their
health status, including whether they had subsequent plastic surgery as well as
lifestyle factors that could affect their health (menstrual, pregnancy, and
breast-feeding history, weight, hormone use, cigarette smoking, alcohol
consumption, and medical history). Extensive data on the potential short-term
(rupture) and longer-term complications (cancer, connective tissue diseases,
symptoms of connective tissue disease) were also obtained through the
questionnaire.
No clinical examinations were done on the living patients for this study.
Attempts were made to verify patient reports of cancer and connective tissue
diseases by retrieving medical records from physicians who had diagnosed or
treated these diseases. Death certificates were collected for the patients who
had died to verify the causes of death.
About 80 percent of the original 13,500 implant patients and 4,000 controls
were successfully traced. About 70 percent of those traced as alive completed
the questionnaires. These percentages are similar to other comparably designed
epidemiologic studies.
6. How do the characteristics of women with breast implants compare to women in
the general population?
Previous studies have shown that breast implant patients are different from the
general population in a number of ways. Some studies have reported that implant
patients tend to have different reproductive and medical histories and
different lifestyle characteristics. 7. How do the characteristics of the women in
this study compare to other plastic surgery patients?
The authors of the current study published a paper in the March 2000 issue of Plastic
and Reconstructive Surgery
characterizing a subset of the participants. Data collected from 7,447 breast
implant patients and 2,203 patients with other types of plastic surgery showed
that implant patients were significantly more likely than other plastic surgery
patients to be white, to have less education, to have early ages at first
birth, to be thin, and to be screened frequently for breast disease. However,
there were no differences between the two groups with respect to family income,
number of pregnancies, alcohol consumption, cigarette smoking, histories of
previous gynecologic operations, or operations for benign breast disease.
Therefore, the authors believe that other plastic surgery patients may be a
more appropriate comparison group than women in the general population for
studies of the health effects of breast implants.
8. What is unique about this study?
This is one of the longest and largest studies to date on the health effects of
breast implants. Most previous investigations have looked at the effects of
implants over a shorter time period, typically less than 10 years. Besides the
short follow-up periods, previous studies have been too small to evaluate rare
diseases.
In addition, previous reports have not included information about types of
devices implanted or risk factors affecting health, such as medical history,
screening practices, and lifestyle behaviors (see question 5). All of these
factors are included in the current NCI study.
Another unique feature of this study is that the investigators compared the
breast cancer risks of the implant patients to both the general population and
other plastic surgery patients. Previous studies have generally used only the
general population for a comparison group, except for a recent Swedish study
that compared women with implants to those with breast reduction procedures.
9. How do these results compare to other breast implant studies?
Breast cancer risk:
A number of previous studies have evaluated the relationship between breast
implants and subsequent breast cancer risk. Most have shown that the risk of
developing breast cancer is less among women with implants compared to women
without implants. In several of the studies, the size of the reduced risk was
as much as 50 percent to 60 percent. However, these studies generally did not
have detailed information on patient characteristics that could affect the
development of breast cancer (see question 5), and had follow-up times of less
than 10 years.
NCI researchers found a slight decrease in breast cancer risk during the
initial 10-year period. However, this decrease was not seen with increasing
follow-up time. The reduced risk immediately after implantation may have
reflected the effect of pre-implantation screening; i.e., women at high risk
for breast cancer were unlikely to have received implants. The average length
of follow-up in the NCI study was 12.9 years among the implant patients vs.
11.6 years among the comparison patients. Type of implant:
Previous studies have not included detailed information about types of
implants. The women in this study had cosmetic surgery between 1962 and 1988,
during a time when a great number of changes were taking place in the
manufacturing of breast implants such as the shell thickness, the type of shell
coating, and the gel composition. This is the first study to look across such a
long time-frame and show that the type of implant had no effect on breast
cancer risk. Stage at diagnosis and breast cancer mortality:
Some clinical studies have suggested that women with breast implants have more
advanced breast cancer when diagnosed than women without breast implants.
However, in two larger epidemiologic studies, there did not appear to be
differences in stage at diagnosis or survival rates among the two groups.
In the current study, NCI researchers found a shift toward somewhat later
detection of breast cancers among the implant patients compared to the
controls. Even though the differences were not statistically significant, there
were consistently smaller percentages of in situ (early-stage) cancers among
the implant patients. However, there was no significant difference in breast
cancer mortality between the implant and comparison patients. This finding
consistent with the one other study that looked at this issue. The authors
recommended further surveillance of breast cancer death rates among implant
patients.
10. Whats the difference between silicone implants and saline implants?
Implants are soft silicone sacs, inflated with either saline solution (salt
water) or a synthetic silicone gel. Until 1992, when the FDA banned
silicone-filled implants (except for use in controlled clinical trials among
women seeking breast reconstruction), 90 percent to 95 percent of the implants
contained the silicone gel because it had a more pleasing look and feel than
the saline-filled implants. Since the 1992 ban, 90 percent to 95 percent of the
implants have been saline-filled.
11. Does the study distinguish between the effects of saline and silicone
implants?
Yes, the study includes women with saline and silicone implants, but no altered
breast cancer risk was associated with either type of implant. Of all the
implant patients in the study, 49.7 percent received silicone gel implants,
34.1 percent double lumen implants, 12.2 percent saline-filled implants, 0.1
percent other types of implants, and 3.8 percent unspecified types of implants.
Double lumen implants have two shells; the inner sac is filled with silicone
gel and the outer with saline. .
12. Does the study address the health effects of breast cancer patients who
receive implants for breast reconstructive surgery?
No, not directly. The participants in the study were limited to women who
received breast implants for cosmetic reasons and did not include breast cancer
patients.
About 80 percent of breast implants in the United States are for cosmetic
surgery and 20 percent for breast reconstruction. The majority of previous
studies have focused on women who received implants for cosmetic reasons.
13. What have other studies shown about the risk of breast cancer in women
undergoing breast reconstruction after breast cancer surgery?
Less is known about the risk of breast cancer following reconstructive surgery
compared to cosmetic surgery. One small study reported no increase in the
development of second primary breast cancer in women with silicone implants
following mastectomy compared to women who received mastectomies without
implants. The small size of the study, however, limits the conclusions.
Any study of the risks of breast cancer or other cancers with women who receive
reconstructive implants is more complicated than one involving women with
cosmetic implants because it needs to take into account the effects of
different breast cancer treatments. A study with breast cancer patients would
best be done in the context of a clinical trial where comparisons can be made
between women who choose to have reconstruction and those who do not, but who
otherwise have received identical treatments.
14. What measures were taken to ensure the objectivity of the study?
-
The study was funded entirely by the government, not by plastic surgeons,
implant manufacturers, or other special interest groups.
-
Government scientists, not manufacturers of implants or plastic surgeons,
designed and provided scientific oversight for the study.
-
To participate in the study, plastic surgeons had to agree to allow
investigators to see all of their records, not just records for selected
patients.
-
Information gathered through the participant questionnaire about diseases such
as cancer or connective tissue disorders was confirmed by the medical records
of oncologists, rheumatologists, and other physicians who had seen the study
respondents for these illnesses.
-
The investigators obtained detailed information on other factors which could
affect health status.
-
Death certificates were collected for the patients identified as deceased to
verify the causes of death.
-
Scientific oversight for the study is provided by NCIs Board of Scientific
Counselors and its Breast Implant Study Advisory Panel, a multidisciplinary
panel of national experts and consumer representatives.
15. What is the role of the Breast Implant Study Advisory Panel?
The role of the advisory panel has been to provide continuing scientific review
of the study. The panel is made up of academic scientists, including
oncologists, plastic surgeons, rheumatologists, epidemiologists, and patient
advocates. The panel meets regularly with the researchers to address issues
involving data analysis and interpretation, and reports to NCIs Board of
Scientific Counselors.
16. Does NCI have a role in the legal actions against manufacturers?
No, NCI does not have a role. Contrary to some reports, the attorneys
representing women who were taking legal action against the manufacturers of
the implants were not consulted by NCI investigators as to which plastic
surgery practices to include in the study. A number of professional plastic
surgery organizations, including the American Society of Plastic and
Reconstructive Surgeons and the American Aesthetic Society, were consulted to
help identify long-standing practices in which at least 500 cosmetic operations
were done prior to 1989 and in which the surgeons retained complete records and
were willing to give the researchers complete access to them. The NCI
investigators performed their own review of the patient records.
Louise A. Brinton, Ph.D., principal investigator for the study, interacted with
plaintiff attorneys on two occasions in 1995 in order to encourage the
attorneys not to dissuade their clients from participating in the NCI study.
The researchers had similar discussions with a number of advocacy groups. A
fact sheet was developed to address several misconceptions about the research
and was widely disseminated to various breast implant advocacy groups, plastic
surgeons and their professional organizations, and lawyers.
17. Who are the investigators in this study?
Brinton is chief of the Environmental Epidemiology Branch in NCIs Division of
Cancer Epidemiology and Genetics (DCEG). Additional NCI investigators are Jay
H. Lubin, Ph.D., and Robert N. Hoover, M.D., also from DCEG, and S. Lori Brown,
Ph.D., research scientist from the FDAs Center for Devices and Radiological
Health in Rockville, Md. Theodore Colton, Sc.D., from the Department of
Epidemiology and Biostatistics at the Boston University School of Public Health
in Massachusetts, was under contract with the study team as was Mary Cay Burich
from Abt Associates Inc., in Chicago, who assisted with specific data
collection tasks.
18. What are the publications so far from the NCI breast implant study?
Brinton L.A., Brown S.L., Colton T., Burich M.C., Lubin J. Characteristics of a
Population of Women with Breast Implants Compared with Women Seeking Other
Types of Plastic Surgery. Plastic and Reconstructive Surgery
2000;105(3):919-27. Brinton L.A., Lubin J.H., Burich M.C., Colton T., Brown S.L.,
Hoover R.N. Breast Cancer Following Augmentation Mammoplasty (United States). Cancer
Causes and Control
2000;11(9): 819-827.
Brinton LA, Lubin JH, Burich MC, et al. Cancer Risk at Sites Other than Breast Following Augmentation Mammoplasty. Annals of Epidemiology May 2001; 11(4):248-256.
Brinton LA, Lubin JH, Burich MC, et al. Mortality Among Augmentation Mammoplasty Patients. Epidemiology May 2001;12(3):321-326.
Brinton LA, Buckley LM, Dvorkina O, et al. Risk of Connective Tissue Disorders among Breast Implant Patients. American Journal of Epidemiology; 2004;160; 619-627.
Brinton LA, Lubin JH, Murray MC, et al. Mortality Rates Among Augmentation Mammoplasty Patients: An Update. Epidemiology March 2006; 17(2): 162-169.
19. What additional studies with this cohort are underway?
Analyses of the causes of mortality and the occurrence of cancers other than
breast cancer are in process and similar analyses of connective tissue
disorders will follow.
Back to Top |